# Evidence pack — AstraZeneca

- **Slug:** astrazeneca
- **Legal name:** AstraZeneca PLC
- **Ticker / MIC:** AZN · XSTO
- **Date range:** 2026-02-02 → 2026-08-10
- **Generated at:** 2026-08-10T18:07:56.213Z
- **Mode:** LIVE
- **Newest source success:** 2026-08-10T18:01:52.957Z

## Market context disclaimer

Price context and the events below may be relevant research context and **do not establish causation**. This pack is not investment advice, a recommendation, or a forecast.

## Chronological evidence

### 2026-04-02 — AstraZeneca: Imfinzi+Imjudo improves PFS in early liver cancer

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 34909951-2b7d-4e19-abe7-2747530f2e56
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-imfinzi-imjudo-improves-pfs-in-early-liver-cancer-f2b456b0

### 2026-04-10 — AstraZeneca: Alexion data at 2026 AAN Annual Meeting reflects industry-leading portfolio and commitment to enhancing care across rare diseases

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** d52bf47c-5199-44df-9240-8874cde026ea
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-alexion-data-at-2026-aan-annual-meeting-reflects-industry-leading-portfolio-and-commitment-to-enhancing-care-across-rare-diseases-4b3ded1e

### 2026-04-20 — AstraZeneca: Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 0d50eade-12e5-4fa0-b902-56d3e310877b
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-tozorakimab-met-primary-endpoint-in-phase-iii-miranda-trial-in-patients-with-copd-29ee5a85

### 2026-04-21 — AstraZeneca: Ultomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with immunoglobulin A nephropathy in I CAN Phase III trial

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** e595c9d5-53de-4432-a691-e218808f82db
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-ultomiris-demonstrated-statistically-significant-and-clinically-meaningful-reduction-of-proteinuria-in-adults-with-immunoglobulin-a-nephropathy-in-i-can-phase-iii-trial-63011d46

### 2026-04-23 — Change to AstraZeneca Board of Directors

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** a4c93eb2-40a4-469f-9d38-7100616ea13d
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/change-to-astrazeneca-board-of-directors-154a1df9

### 2026-04-27 — AstraZeneca: Saphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 8a8be43c-c35b-4387-8308-61edef73511b
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-saphnelo-approved-in-the-us-for-subcutaneous-self-administration-as-a-new-autoinjector-for-the-treatment-of-systemic-lupus-erythematosus-8d1b4ed7

### 2026-04-28 — AstraZeneca: Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 5815035a-82a4-4955-99b6-2237c9565c82
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-breztri-approved-in-the-us-for-asthma-as-first-and-only-triple-therapy-for-patients-12-years-of-age-and-older-a3959b18

### 2026-04-29 — Resultat för AstraZeneca: Första kvartalet 2026

- **Type:** announcement
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 0f51e909-edd9-4b97-b422-b210a3b7efd0
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/resultat-for-astrazeneca-forsta-kvartalet-2026-30dacd03

### 2026-05-04 — AstraZeneca: Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 85668754-c0e1-4dd6-99c0-ac2b1eb349bd
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-update-on-fda-advisory-committee-vote-on-camizestrant-in-combination-with-a-cdk4-6-inhibitor-for-advanced-hr-positive-breast-cancer-b25d2345

### 2026-05-04 — AstraZeneca: Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 43fd0832-fb39-45fa-89a2-54f182366d8f
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-truqap-recommended-by-fda-advisory-committee-for-pten-deficient-metastatic-hormone-sensitive-prostate-cancer-96d229b8

### 2026-05-12 — AstraZeneca: Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 86e566ab-3f4f-4e1e-b39b-082fc5c3b2d5
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-eneboparatide-normalised-serum-calcium-and-achieved-independence-from-active-vitamin-d-and-oral-calcium-supplements-in-31-1-of-adults-with-hypoparathyroidism-at-week-24-in-calypso-phase-iii-trial-559a043c

### 2026-05-14 — AstraZeneca: Imfinzi + EV improves EFS & OS in bladder cancer

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** b7e5b884-a0a9-4c48-8b3a-23e9da28bfcd
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-imfinzi-ev-improves-efs-and-os-in-bladder-cancer-6a272887

### 2026-05-18 — AstraZeneca: Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 4e65411a-4ac9-4f7e-bc8c-b6932d180ba7
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-baxfendy-approved-in-the-us-as-the-first-and-only-aldosterone-synthase-inhibitor-treatment-for-adults-with-hypertension-86cabc2b

### 2026-05-18 — AstraZeneca: Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 519cb604-d6fb-4fed-8a30-7b1b0f9070ae
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-enhertu-approved-in-the-us-for-two-new-indications-for-patients-with-her2-positive-early-breast-cancer-83f3ec69

### 2026-05-22 — AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 90cb6582-7638-4e21-abcb-681c94aedf4f
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-to-showcase-phase-iii-data-in-liver-breast-and-bladder-cancers-and-potential-first-in-class-rare-disease-therapy-at-asco-2026-6ca134e1

### 2026-05-22 — AstraZeneca: Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** ae4bdd93-514d-4580-9c9e-3e803ee4320e
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-camizestrant-in-combination-with-a-cdk4-6-inhibitor-recommended-for-approval-in-the-eu-by-chmp-for-1st-line-advanced-er-positive-breast-cancer-e3bc1fe6

### 2026-05-22 — AstraZeneca: Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 7513940f-0bd5-49b2-8c6a-f949c9a57077
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-previously-treated-her2-positive-metastatic-solid-tumours-9ed7d71f

### 2026-05-22 — AstraZeneca: Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 95280d1c-339e-4c61-9c3f-91043a5c1a04
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-datroway-approved-in-the-us-as-first-trop2-directed-antibody-drug-conjugate-for-1st-line-treatment-of-patients-with-metastatic-triple-negative-breast-cancer-who-are-not-pd-1-pd-l1-inhibitor-candidates-c237f67b

### 2026-05-27 — AstraZeneca: US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 62e7e878-a0be-48eb-8704-b3dde9513e92
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-us-fda-decision-date-extended-for-serena-6-filing-of-camizestrant-to-enable-review-of-additional-data-c47af0b4

### 2026-05-29 — AstraZeneca: Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** d4378942-f697-4b09-ac0a-bd29c38061b9
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-imfinzi-approved-in-the-us-in-first-and-only-immunotherapy-combination-for-patients-with-bcg-naive-high-risk-non-muscle-invasive-bladder-cancer-05a7977f

### 2026-05-29 — AstraZeneca: CARES Phase III clinical programme did not meet primary endpoint in overall AL amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa AL amyloidosis

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** ff5ad77d-3749-445d-acf4-f8d7cfb028e0
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-cares-phase-iii-clinical-programme-did-not-meet-primary-endpoint-in-overall-al-amyloidosis-population-however-demonstrated-anselamimab-as-potential-first-anti-fibril-therapy-in-kappa-al-amyloidosis-8daadb42

### 2026-06-01 — AstraZeneca: Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 9ff0f266-9d13-4ee5-9b0b-9c5291c3025b
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-imfinzi-plus-imjudo-combined-with-lenvatinib-and-tace-reduced-the-risk-of-disease-progression-or-death-by-30-in-embolisation-eligible-unresectable-liver-cancer-in-emerald-3-phase-iii-trial-9a806cf7

### 2026-06-02 — AstraZeneca: Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 mutation in SERENA-6 trial

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** 38d1e2b1-c9e8-4448-b5a7-1878f56e009d
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-camizestrant-combination-delayed-time-to-first-progression-by-55-and-to-second-progression-by-37-in-patients-with-advanced-hr-positive-breast-cancer-with-an-emergent-esr1-mutation-in-serena-6-trial-742541f6

### 2026-06-06 — AstraZeneca: Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo in adults with immunoglobulin A nephropathy at 34 weeks in I CAN Phase III trial

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** c72fca50-3945-4aca-9a36-402ece2eebe7
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-ultomiris-demonstrated-43-4-reduction-in-proteinuria-vs-placebo-in-adults-with-immunoglobulin-a-nephropathy-at-34-weeks-in-i-can-phase-iii-trial-76c062fd

### 2026-06-08 — Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca's cardiometabolic and kidney portfolio

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** d87e4880-ba54-4ff7-805f-ba848cd8c660
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/elecoglipron-an-oral-small-molecule-glp-1-ra-moves-to-phase-iii-programme-and-unlocks-next-chapter-in-astrazenecas-cardiometabolic-and-kidney-portfolio-7aac4f07

### 2026-06-15 — AstraZeneca: Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** fe60f659-2d63-4db0-8bb4-856fdc5c0d29
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-truqap-combination-approved-in-the-us-as-first-and-only-targeted-treatment-for-pten-deficient-metastatic-hormone-sensitive-prostate-cancer-5bf479ed

### 2026-06-15 — AstraZeneca: Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0
- **Evidence IDs:** ae7a11cd-e75e-4aa0-8262-03b29fc5ea88
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-ultomiris-granted-priority-review-in-the-us-as-treatment-for-adults-with-immunoglobulin-a-nephropathy-2b210859

### 2026-06-26 — AstraZeneca: Datroway[ ]recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0002
- **Evidence IDs:** 6838b94d-c2f9-498f-8bf6-4f1514c232f5
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-datroway-recommended-for-approval-in-the-eu-by-chmp-as-1st-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-who-are-not-candidates-for-immunotherapy-04866bfd

### 2026-06-29 — AstraZeneca: Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0002
- **Evidence IDs:** 7e94649a-a827-4f67-984c-1b938cde9577
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-enhertu-approved-in-the-eu-as-first-tumour-agnostic-her2-directed-therapy-and-antibody-drug-conjugate-for-patients-with-previously-treated-her2-positive-metastatic-solid-tumours-4dab3b64

### 2026-06-29 — Efzimfotase alfa showed bone health improvements in treatment-naïve paediatric patients with hypophosphatasia: median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase 3 trial

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0002
- **Evidence IDs:** 18253382-4648-466c-9875-2a9f167954a3
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/efzimfotase-alfa-showed-bone-health-improvements-in-treatment-naive-paediatric-patients-with-hypophosphatasia-median-difference-of-1-67-vs-placebo-in-rgi-c-score-at-week-25-in-mulberry-phase-3-trial-43c4afd7

### 2026-07-09 — AstraZeneca: Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0014
- **Evidence IDs:** 13d0dfdf-162d-432f-b13c-9998a3481d1b
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-update-on-cardio-ttransform-phase-iii-trial-for-wainua-eplontersen-in-adults-with-transthyretin-mediated-amyloid-cardiomyopathy-08a345de

### 2026-07-14 — AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0033
- **Evidence IDs:** 67fb7e0b-d847-49a3-8c4f-43afdec7a04f
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-enters-exclusive-global-license-agreement-for-novel-oral-egfr-inhibitor-zegfrovy-for-lung-cancer-with-dizal-pharmaceutical-810225cc

### 2026-07-15 — Barometerindikatorn: 104.7 (+2.6)

- **Type:** macro
- **Source:** Konjunkturinstitutet barometer (`nier-konj`) · Tier 1
- **Confidence:** 0.0048
- **Evidence IDs:** bffd7d89-d8ad-419a-ba47-68578ed7c90c
- **Canonical link:** https://www.konj.se/publikationer/konjunkturbarometern/

### 2026-07-23 — AstraZeneca: Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0156
- **Evidence IDs:** f7809da0-0f01-4fa6-be36-b9feac79412f
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-etcamah-camizestrant-in-combination-with-a-cdk4-6-inhibitor-approved-in-the-eu-for-1st-line-advanced-er-positive-breast-cancer-9d264d0f

### 2026-07-24 — AstraZeneca: Trixeo recommended for approval in the EU by CHMP for the maintenance treatment of asthma

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0192
- **Evidence IDs:** 3ccba11d-59d8-4745-942f-30cb48e2c3ac
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-trixeo-recommended-for-approval-in-the-eu-by-chmp-for-the-maintenance-treatment-of-asthma-0e1f4ecb

### 2026-07-24 — AstraZeneca: Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0192
- **Evidence IDs:** ee67a3c5-1ce5-4db3-a3bc-5f9869f08124
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-enhertu-plus-pertuzumab-recommended-for-approval-in-the-eu-by-chmp-as-1st-line-treatment-for-patients-with-her2-positive-metastatic-breast-cancer-56706f25

### 2026-07-27 — AstraZeneca: Half-year Financial Report

- **Type:** announcement
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0398
- **Evidence IDs:** 7efe9afc-af43-4e11-91a9-789f509288a4
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-half-year-financial-report-12dc3573

### 2026-07-27 — Resultat för AstraZeneca: Första halvåret samt andra kvartalet 2026

- **Type:** announcement
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0398
- **Evidence IDs:** e66df37c-59c9-470d-a2d5-f022452ef3fb
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/resultat-for-astrazeneca-forsta-halvaret-samt-andra-kvartalet-2026-9c1c6863

### 2026-07-27 — AstraZeneca: Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0312
- **Evidence IDs:** 22bd7c62-6977-4dc5-80b4-fe03b958497e
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-sonesitatug-vedotin-demonstrated-a-statistically-significant-and-highly-clinically-meaningful-improvement-in-overall-survival-in-2nd-and-later-line-cldn18-2-positive-advanced-gastric-gej-cancers-19914c96

### 2026-07-27 — AstraZeneca: Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0312
- **Evidence IDs:** dacda0a9-7e0c-4a98-b9c7-76f38f8036fa
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-update-on-phase-iii-trial-of-ultomiris-in-adults-and-adolescents-with-thrombotic-microangiopathy-after-haematopoietic-stem-cell-transplant-92242320

### 2026-07-31 — AstraZeneca: Datroway[ ]approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy

- **Type:** news
- **Source:** Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · Tier 1
- **Confidence:** 0.0626
- **Evidence IDs:** 63b352ce-6d51-46b9-9afe-5d4f00915874
- **Canonical link:** https://mfn.se/cis/a/astrazeneca/astrazeneca-datroway-approved-in-the-eu-as-only-trop2-directed-medicine-with-overall-survival-benefit-for-the-1st-line-treatment-of-patients-with-metastatic-tnbc-who-are-not-candidates-for-immunotherapy-3b89418a

### 2026-08-09 — Riksbank policy rate at 1.75%

- **Type:** macro
- **Source:** Riksbanken rates & FX (SWEA) (`riksbank-rates-fx`) · Tier 1
- **Confidence:** 0.3717
- **Evidence IDs:** 726abb0b-5c66-4cbe-bfd6-2d9b237a24ba
- **Canonical link:** https://www.riksbank.se/en-gb/statistics/interest-rates-and-exchange-rates/

## Source freshness (excerpt)

- GLEIF LEI API (`gleif-lei`) · public · last success 2026-08-10T17:59:33.852Z
- Nasdaq Nordic company announcements (`nasdaq-company-announcements`) · public · last success 2026-08-10T17:59:35.619Z
- Issuer IR via MFN (press rooms) (`issuer-ir-mfn`) · public · last success 2026-08-10T18:00:20.638Z
- NGM / Spotlight announcements (`ngm-spotlight-announcements`) · public · last success 2026-08-10T18:00:20.998Z
- FI fondinnehav (`fi-fund-holdings`) · public · last success 2026-08-10T18:01:33.369Z
- FI Prospektregistret (`fi-prospectus-register`) · public · last success 2026-08-10T18:01:34.799Z
- FI supervised entities (`fi-supervised-entities`) · public · last success 2026-08-10T18:01:36.270Z
- Finansinspektionen net short positions (`fi-short-positions`) · public · last success 2026-08-10T17:56:47.325Z
- Finansinspektionen major holdings (flaggning) (`fi-major-holdings`) · public · last success 2026-08-10T17:57:47.450Z
- FI Varningslistan (`fi-warning-list`) · public · last success 2026-08-10T17:57:49.052Z
- Riksbanken rates & FX (SWEA) (`riksbank-rates-fx`) · public · last success 2026-08-10T17:57:55.341Z
- Riksbanken Swestr (`riksbank-swestr`) · public · last success 2026-08-10T17:58:01.387Z

---
Generated by Stockholm Insider · research tools only · not investment advice.